Soligenix

Soligenix EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Soligenix (SNGX) as of Oct 16, 2026 is -0.40. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -0.63 — a change of -36.91% (higher).

EV/EBITDA

-0.40

YoY

-36.91%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Soligenix is 2025 -0.40 . EV/EBITDA (Enterprise Value to EBITDA) of Soligenix was 2024 -0.63 . It decreases by -36.91% higher compared to the previous year.

The Soligenix EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-0.37 USD
Jan 1, 2019
-0.67 USD
Jan 1, 2020
-0.22 USD
Jan 1, 2021
0.30 USD
Jan 1, 2022
-0.65 USD
Jan 1, 2023
-0.96 USD
Jan 1, 2024
-0.63 USD
Jan 1, 2025
-0.40 USD
The Soligenix EV/EBITDA history
YEAREV/EBITDAYoY
-0.40-36.91%
-0.63-33.99%
-0.96+47.40%
-0.65-316.08%
0.30-235.24%
-0.22-66.56%
-0.67+81.43%
-0.37-38.07%
-0.59-4.31%
-0.62-42.70%
-1.08+9.92%
-0.98—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

EV/EBITDA (Enterprise Value to EBITDA) of Soligenix is -0.40 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Soligenix changed from -0.63 to -0.40, representing a -36.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Soligenix since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Soligenix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Soligenix

All Key Metrics — Soligenix